Versant Ventures

Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform
Versant funds TCR therapy biotech T-knife's $78M+ Series A to boost humanized T cell mice platform
Endpoints
Versant Ventures
venture capital
T-knife
Flag link:
A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer
A protein engineering platform spawns a new IL-2 player out of Basel, with human trials looming next summer
Endpoints
protein engineering
Bright Peak Therapeutics
Versant Ventures
Flag link:
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work
Xconomy
Bayer
Versant Ventures
cell therapy
M&A
BlueRock Therapeutics
Flag link:
Century Therapeutics Launches with $250 Million for Induced Pluripotent Stem Cell Platform
Century Therapeutics Launches with $250 Million for Induced Pluripotent Stem Cell Platform
BioSpace
Century Therapeutics
Versant Ventures
iPSC
solid tumors
Flag link:
Bayer powers Versant cell therapy startup to $250M round
Bayer powers Versant cell therapy startup to $250M round
Fierce Biotech
Versant Ventures
Century Therapeutics
cell therapy
Bayer
venture capital
Flag link:
Versant Raises $100 Million to Develop Venture Ecosystem in Canadian Life Sciences Arena
Versant Ventures
Canada
Flag link:
Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own
Versant partners gear up for a $700M bonanza of biotech bets, with a special focus all their own
Endpoints
Versant Ventures
biotech
venture capital
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche Acquires MS Remyelination Program from Versant Ventures
CP Wire
Roche
MS
multiple sclerosis
remylination
M&A
Versant Ventures
Inception 5
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche
Versant Ventures
multiple sclerosis
Flag link:
Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts
Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts
Endpoints
biotech
venture capital
Versant Ventures
Flag link:
Bayer, Versant close $225m Series A to launch stem cell company
Bayer, Versant close $225m Series A to launch stem cell company
Mass Device
Bayer
Versant Ventures
stem cells
Series A
BlueRock Therapeutics
devices
regenerative medicine
Flag link:
[video]Drugmakers Build to Buy
[video]Drugmakers Build to Buy
Motley Fool
Biogen Idec
Atlas Venture
Celgene
Versant Ventures
GSK
Avalon Ventures
JNJ
Flag link: